News

The study is an open-label, dose-escalating trial which is designed to evaluate the safety and immunogenicity of DPX-0907 in patients with advanced stage breast, ovarian or prostate cancer.

GI-4000 and GI-6207 vaccines are used to target mutated versions of the Ras oncoprotein and CEA expressing tumors respectively. In the first study, GI-4000, a series of Tarmogen

The patent recognizes the company’s intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds. Setrobuvir, which has received fast track

Under the agreement, PeptLab will continue to provide support in technical inputs for developing Biotage related products. Additionally, PeptLab will also offer training facilities for demonstrating Biotage’s range

The company is organizing a multi-center Phase 3 trial investigating asimadoline in D-IBS, conducted under a Special Protocol Assessment agreement with the FDA for US registration. Tioga Pharma

RBM’s protein detection platform offers pharmaceutical companies with critical information for accelerating drug development research and improve clinical trial outcomes. The company’s proprietary Multi Analyte Profiling (MAP) technology

Completion of the study enables Fero Industries to move forward with plans for registration, licensing and distribution of Sucanon across the Middle East. The pre-clinical and clinical studies

The trial which is sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), expects to recruit around

The results from the trial showed an objective response rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine